Adrenal Insufficiency Clinical Trial
Official title:
Mass Spectrometry Based Cutoffs for Cortisol and 17-hydroxy-progesterone (17-OH-progesterone) After Stimulation Tests for Primary and Secondary Adrenal Insufficiency.
NCT number | NCT02818660 |
Other study ID # | 2016/174 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 21, 2016 |
Est. completion date | December 21, 2017 |
Verified date | February 2024 |
Source | Haukeland University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
There are two main stimulation tests used to decide if a patient has cortisol deficiency. It is the "synacthen test", were we stimulate the patient with intramuscular or intravenous synacthen ( ACTH) to see how much cortisol the adrenals are capable of producing, and it is the "Insulin hypoglycemia test" were we give the patient insulin to provoke a hypoglycemia, and look at the adrenal response to that stimulus. The cut off values for a normal response is based on old immunological assays no longer in use. Assays with a lot of interference and cross reactivity leading to measurement of higher values for cortisol than what we measure on the highly specific LCMS/MS ( Liquid chromatography mass spectrometry methode) that we are using for cortisol today. So, there is a need for new cut off values for a normal response to such tests. The purpose of this study is to produce such new cutoff values by performing the test in 120 healthy controls. We also want to perform the test in patient groups normally going trough this tests according to the same protocol as the control persons, to evaluate the new cutoffs in different patient groups.
Status | Completed |
Enrollment | 232 |
Est. completion date | December 21, 2017 |
Est. primary completion date | December 21, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Healthy individuals not using any corticosteroids . - Patients with clinical suspicion of primary or secondary adrenal insufficiency. -Patient suspicious of having an enzyme defect ( 21 hydroxylase deficiency) giving hirsutism. Exclusion Criteria: -Use of corticosteroids. |
Country | Name | City | State |
---|---|---|---|
Norway | Haukeland University hopsital | Bergen |
Lead Sponsor | Collaborator |
---|---|
Haukeland University Hospital |
Norway,
Ueland GA, Dahl SR, Methlie P, Hessen S, Husebye ES, Thorsby PM. Adrenal steroid profiling as a diagnostic tool to differentiate polycystic ovary syndrome from nonclassic congenital adrenal hyperplasia: pinpointing easy screening possibilities and normal — View Citation
Ueland GA, Methlie P, Oksnes M, Thordarson HB, Sagen J, Kellmann R, Mellgren G, Raeder M, Dahlqvist P, Dahl SR, Thorsby PM, Lovas K, Husebye ES. The Short Cosyntropin Test Revisited: New Normal Reference Range Using LC-MS/MS. J Clin Endocrinol Metab. 2018 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Define a cutoff level for serum cortisol after stimulation with synacthen or hypoglycemia in healthy control persons. | s-cortisol | 2 year | |
Secondary | Define a cutoff level for serum 17-OH-progesterone after stimulation with synacthen or hypoglycemia in healthy control persons. | s-17-OH-progesterone | 2 year | |
Secondary | Define a cutoff level for saliva cortisol after stimulation with synacthen or hypoglycemia in healthy control persons. | saliva cortisol | 2 year | |
Secondary | Define a cutoff level for saliva 17-OH-progesterone after stimulation with synacthen or hypoglycemia in healthy control persons. | saliva 17-OH-progesterone | 2 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT03282487 -
Optimising Steroid Replacement in Patients With Adrenal Insufficiency
|
Phase 4 | |
Not yet recruiting |
NCT06435481 -
Tolerability and Acceptance of Two Oral Hydrocortisone Compounding Formulation for Pediatrics
|
Phase 4 | |
Not yet recruiting |
NCT05716607 -
Treatment Study in Patients Treated With Both Insulin & Hydrocortisone
|
N/A | |
Recruiting |
NCT03399383 -
Adherence in Chronic Adrenal Insufficiency
|
N/A | |
Completed |
NCT01428336 -
Value of 25 mcg Cortrosyn Stimulation Test
|
N/A | |
Completed |
NCT00851942 -
Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test
|
Phase 4 | |
Withdrawn |
NCT00368381 -
Hydrocortisone Versus Hydrocortisone Plus Fludrocortisone for the Treatment of Adrenal Insufficiency in Severe Sepsis
|
Phase 4 | |
Active, not recruiting |
NCT04519580 -
Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
|
||
Recruiting |
NCT06008184 -
Real-time Monitoring of Cortisol - Comparison of Cortisol Levels in Four Biological Fluids
|
||
Completed |
NCT03013166 -
THIN Database Study: Resource Use and Outcomes in Patients With Adrenal Insufficiency Prescribed Hydrocortisone: Immediate, or Modified Release, or Prednisolone
|
||
Enrolling by invitation |
NCT02282150 -
Modified-release Compared to Conventional Hydrocortisone on Diurnal Fatigue in Secondary Hypoadrenalism
|
Phase 4 | |
Completed |
NCT02934399 -
Dynamic Hormone Diagnostics in Endocrine Disease
|
||
Completed |
NCT03000231 -
Circadian Function and Cardio-metabolic Risk in Adrenal Insufficiency
|
||
Completed |
NCT01960530 -
An Investigational Study of Hydrocortisone
|
Phase 1 | |
Completed |
NCT00552487 -
Isolated ACTH Deficiency in Patients With Hashimoto Thyroiditis
|
N/A | |
Completed |
NCT00575341 -
Dehydroepiandrosterone Substitution in Adolescent and Young Women With Central Adrenal Insufficiency
|
Phase 3 | |
Completed |
NCT00471900 -
Six Months DHEA Treatment in Female Adrenal Failure
|
N/A | |
Completed |
NCT03294876 -
Rheumatoid Arthritis Adrenal Recovery Study
|
||
Completed |
NCT03709381 -
Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study
|
Early Phase 1 | |
Recruiting |
NCT05639127 -
The Treatment of Adrenal Crisis With Inhaled Prednisolone
|
Early Phase 1 |